MU vs PFE: Which Is the Better Buy?
Side-by-side comparison of Micron Technology, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Micron Technology, Inc. · Technology
$1,080.53
+4.1% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MU |
PFE |
| Current Price |
$1,080.53 |
$27.64 |
| Fair Value Estimate |
$1,124.98 |
$30.94 |
| Upside to Fair Value |
+4.1%
|
+12.0%
|
| Market Cap |
$1,220.3B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.6x
|
17.4x
|
| Price / Sales |
13.5x
|
2.5x
|
| Price / FCF |
46.6x
|
14.3x
|
| Revenue Growth YoY |
+345.7%
|
+2.6%
|
| Gross Margin |
72.6%
|
71.3%
|
| Operating Margin |
65.7%
|
25.1%
|
| Return on Equity |
70.5%
|
4.9%
|
| Dividend Yield |
0.05% |
6.22% |
| FCF Yield |
2.15%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Micron Technology is a global leader in advanced semiconductor memory and storage, operating across Compute and Networking, Mobile, Storage, and Embedded segments with DRAM, NAND, and NOR products sold under the Micron and Crucial brands to cloud, data center, mobile, automotive, and consumer markets. The business quality is high on current fundamentals: TTM gross margin is 72.6%, TTM operating m…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
MU |
PFE |
| Zone Low |
$843.74 |
$23.21 |
| Zone High |
$956.23 |
$26.30 |
| In Buy Zone? |
No
|
No
|